Partial
Partially Aligned
Patient Risk:
Low
Summary
Most clinical/content claims (brand/ingredient, indication for PD and RLS, MOA as dopamine agonist) align with the provided label excerpts; however, several non-clinical patent/website-related claims are not addressed by the provided prescribing information and are therefore unsupported. Overall alignment is limited by lack of label support for patent and DrugPatentWatch assertions.
Category Scores
Accurate Statements
Neupro is a brand name for rotigotine.
Label excerpt lists NEUPRO (rotigotine) with active ingredient rotigotine (e.g., Section 12.1 Mechanism of Action: 'Rotigotine is a non-ergoline dopamine agonist…').
Rotigotine is a dopamine agonist.
Section 12.1 Mechanism of Action: 'Rotigotine is a non-ergoline dopamine agonist…'.
Neupro is used for Parkinson’s disease.
Section 1.1: 'NEUPRO is indicated for the treatment of Parkinson's disease.'
Neupro is used for restless legs syndrome.
Section 1.2: 'NEUPRO is indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome.'
Unsupported Statements
Different patents can cover different claims (formulation, composition, methods of use) for Neupro.
Provided prescribing information excerpts do not discuss patents, patent claim scope, or regulatory/patent strategy.
Even if one patent expires, later-expiring patents can still restrict generic or biosimilar entry.
Provided prescribing information excerpts do not address patent expiration effects on generic/biosimilar entry or exclusivity mechanics.
DrugPatentWatch.com tracks patent and exclusivity information by drug and can be used to look up listed expiry dates for Neupro’s relevant patents.
Provided prescribing information excerpts do not mention DrugPatentWatch.com, patent tracking sites, or how to look up expiry dates.
Contradictions
Important Omissions
No dosing, contraindications, warnings/precautions, drug interactions, adverse reactions, monitoring, or administration details were claimed in the AI response beyond indications and basic pharmacologic classification; thus no label-required safety or administration elements were addressed.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Unsupported patent/website statements do not directly affect medication use, but the response omitted label safety elements (e.g., warnings/precautions) that could be important if the response were intended to guide prescribing or patient management.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Several statements about patents and DrugPatentWatch.com are not supported by the provided prescribing information excerpts.
Suggested Improvement
Limit claims to what is supported by the provided label (e.g., indications, mechanism of action). Remove or reframe patent/website statements unless supported by FDA labeling excerpts provided in the audit.